Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 10/2015

01.10.2015 | Original Article – Cancer Research

Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status

verfasst von: Ann E. Walts, James M. Mirocha, Shikha Bose

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Follicular variant of papillary thyroid carcinoma (FVPTC) is currently treated like conventional papillary thyroid carcinoma (cPTC). Recent reports indicate that encapsulated FVPTC behaves like follicular adenomas, while infiltrative FVPTC behaves like cPTC. This raises the possibility that histology and/or mutation status might help personalize management of FVPTC regarding extent of surgery, intensity of follow-up, and targeted therapy. This study correlates histological features, immunoreactivity for CK19, HBME, and Gal, and BRAF V600E mutation with lymph node (LN) metastasis and follow-up in FVPTC.

Methods

Forty-eight FVPTC (21 with regional lymph node metastasis [LN+] and 27 with negative lymph nodes [LN−]) were reviewed. Demographics, tumor focality, size, circumscription, follicular architecture, lymphovascular invasion, extrathyroidal extension (ETE), and margin status were charted. Macrodissected formalin-fixed paraffin-embedded sections from 47 (21 LN+ and 26 LN−) cases were analyzed for BRAF V600E (1799T>A) mutation using real-time PCR. Correlations between the variables and LN status were calculated.

Results

Sixty-two percent of cases with ETE demonstrated LN metastasis, while 59 % of cases with circumscribed tumors were LN−. In multivariable analysis, ETE and tumor size ≥1 cm were the best predictors of LN+ status, whereas in cases without ETE, the infiltrative pattern and tumor size provided the “best fit.” Immunostains and BRAF mutation status were not helpful. All four tumors that recurred were LN+, with infiltrative borders, and lacked the BRAF mutation.

Conclusions

Tumor circumscription, extrathyroidal extension, and tumor size ≥ 1.0 cm are predictors of lymph node status in FVPTC.
Literatur
Zurück zum Zitat Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA (2006) Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 17:225–234CrossRefPubMed Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA (2006) Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 17:225–234CrossRefPubMed
Zurück zum Zitat Chai YJ, Kim SJ, Kim SC et al (2014) BRAF mutation in follicular variant of papillary thyroid carcinoma is associated with unfavorable clinicopathological characteristics and malignant features on ultrasonography. Clin Endocrinol 81:432–439CrossRef Chai YJ, Kim SJ, Kim SC et al (2014) BRAF mutation in follicular variant of papillary thyroid carcinoma is associated with unfavorable clinicopathological characteristics and malignant features on ultrasonography. Clin Endocrinol 81:432–439CrossRef
Zurück zum Zitat Chem KT, Rosai J (1977) Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases. Am J Surg Pathol 1:123–130CrossRefPubMed Chem KT, Rosai J (1977) Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases. Am J Surg Pathol 1:123–130CrossRefPubMed
Zurück zum Zitat Daniels GH (2011) What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract 17:768–787CrossRefPubMed Daniels GH (2011) What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract 17:768–787CrossRefPubMed
Zurück zum Zitat DeLellis RA, Williams ED (2004) Tumours of the thyroid and parathyroid. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumors. IARC Press, Lyon DeLellis RA, Williams ED (2004) Tumours of the thyroid and parathyroid. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumors. IARC Press, Lyon
Zurück zum Zitat Eloy C, Santos J, Soares P, Sobrinho-Simoes M (2011a) The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 459:265–276CrossRefPubMed Eloy C, Santos J, Soares P, Sobrinho-Simoes M (2011a) The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 459:265–276CrossRefPubMed
Zurück zum Zitat Eloy C, Santos J, Soares P, Sobrinho-Simoes M (2011b) Intratumoral lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. Virchows Arch 459:595–605CrossRefPubMed Eloy C, Santos J, Soares P, Sobrinho-Simoes M (2011b) Intratumoral lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. Virchows Arch 459:595–605CrossRefPubMed
Zurück zum Zitat Gupta S, Ajise O, Dultz L et al (2012) Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse—distinct biologic and clinical entities. Arch Otolaryngol Head Neck Surg 138:227–233CrossRefPubMed Gupta S, Ajise O, Dultz L et al (2012) Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse—distinct biologic and clinical entities. Arch Otolaryngol Head Neck Surg 138:227–233CrossRefPubMed
Zurück zum Zitat Hazard JB, Crile CJ, Dinemore RS, Hawk WA, Kenyon R (1955) Neoplasms of the thyroid. Classification, morphology, and treatment. Arch Pathol Lab Med 59:502–513 Hazard JB, Crile CJ, Dinemore RS, Hawk WA, Kenyon R (1955) Neoplasms of the thyroid. Classification, morphology, and treatment. Arch Pathol Lab Med 59:502–513
Zurück zum Zitat Howitt BE, Jia Y, Sholl LM, Barletta JA (2013) Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid 23:1256–1262CrossRefPubMed Howitt BE, Jia Y, Sholl LM, Barletta JA (2013) Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid 23:1256–1262CrossRefPubMed
Zurück zum Zitat Kim MI, Alexander EK (2012) Diagnostic use of molecular markers in the evaluation of thyroid nodules. Endocr Pract 18:796–802CrossRefPubMed Kim MI, Alexander EK (2012) Diagnostic use of molecular markers in the evaluation of thyroid nodules. Endocr Pract 18:796–802CrossRefPubMed
Zurück zum Zitat Lang BH, Lo CY, Chan WF, Lam AK, Wan KY (2006) Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg 30:752–758CrossRefPubMed Lang BH, Lo CY, Chan WF, Lam AK, Wan KY (2006) Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg 30:752–758CrossRefPubMed
Zurück zum Zitat Lee SR, Jung CK, Kim TE, Bae JS, Jung SL, Choi YJ, Kang CS (2013) Molecular genotyping of follicular variant papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid 23:1416–1422PubMedCentralCrossRefPubMed Lee SR, Jung CK, Kim TE, Bae JS, Jung SL, Choi YJ, Kang CS (2013) Molecular genotyping of follicular variant papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid 23:1416–1422PubMedCentralCrossRefPubMed
Zurück zum Zitat Lindsay S (1964) Pathology of the thyroid gland. In: Pitt-Rivers R, Trotter WR (eds) The thyroid gland, vol 2, 1st edn. Butterworths, Washington, DC, pp 223–270 Lindsay S (1964) Pathology of the thyroid gland. In: Pitt-Rivers R, Trotter WR (eds) The thyroid gland, vol 2, 1st edn. Butterworths, Washington, DC, pp 223–270
Zurück zum Zitat Lindsay S (1960) Carcinoma of the thyroid gland. A clinical and pathologic study of 293 patients at the University of California Hospital. Charles C. Thomas, Springfield Lindsay S (1960) Carcinoma of the thyroid gland. A clinical and pathologic study of 293 patients at the University of California Hospital. Charles C. Thomas, Springfield
Zurück zum Zitat Livolsi V (2003) Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 98:1997CrossRefPubMed Livolsi V (2003) Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 98:1997CrossRefPubMed
Zurück zum Zitat Lloyd RV, Erickson LA, Casey MB et al (2004) Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336–1340CrossRefPubMed Lloyd RV, Erickson LA, Casey MB et al (2004) Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336–1340CrossRefPubMed
Zurück zum Zitat Min HS, Lee C, Jung KC (2013) Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci 28:534–541PubMedCentralCrossRefPubMed Min HS, Lee C, Jung KC (2013) Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci 28:534–541PubMedCentralCrossRefPubMed
Zurück zum Zitat Rhee SJ, Hahn SY, Ko ES, Ryu JW, Ko EY, Shin JH (2014) Follicular variant of papillary thyroid carcinoma: distinct biologic behavior based on ultrasonographic features. Thyroid 24:683–688CrossRefPubMed Rhee SJ, Hahn SY, Ko ES, Ryu JW, Ko EY, Shin JH (2014) Follicular variant of papillary thyroid carcinoma: distinct biologic behavior based on ultrasonographic features. Thyroid 24:683–688CrossRefPubMed
Zurück zum Zitat Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA (2010) Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191–1200CrossRefPubMed Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA (2010) Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191–1200CrossRefPubMed
Zurück zum Zitat Salajegheh A, Petcu EB, Smith RA, Lam AK (2008) Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists. Postgrad Med J 84:78–82CrossRefPubMed Salajegheh A, Petcu EB, Smith RA, Lam AK (2008) Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists. Postgrad Med J 84:78–82CrossRefPubMed
Zurück zum Zitat Scognamiglio T, Hyjek E, Kao J, Chen YT (2006) Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700–708CrossRefPubMed Scognamiglio T, Hyjek E, Kao J, Chen YT (2006) Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700–708CrossRefPubMed
Zurück zum Zitat Virk RK, Van Dyke AL, Finkelstein A et al (2013) BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol 26:62–70CrossRefPubMed Virk RK, Van Dyke AL, Finkelstein A et al (2013) BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol 26:62–70CrossRefPubMed
Zurück zum Zitat Vivero M, Kraft S, Barletta JA (2013) Risk stratification of follicular variant of papillary thyroid carcinoma. Thyroid 23:273–279CrossRefPubMed Vivero M, Kraft S, Barletta JA (2013) Risk stratification of follicular variant of papillary thyroid carcinoma. Thyroid 23:273–279CrossRefPubMed
Zurück zum Zitat Wallander M, Layfield LJ, Jarboe E et al (2010) Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. Appl Immunohistochem Mol Morphol 18:231–235CrossRefPubMed Wallander M, Layfield LJ, Jarboe E et al (2010) Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. Appl Immunohistochem Mol Morphol 18:231–235CrossRefPubMed
Metadaten
Titel
Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status
verfasst von
Ann E. Walts
James M. Mirocha
Shikha Bose
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-1939-9

Weitere Artikel der Ausgabe 10/2015

Journal of Cancer Research and Clinical Oncology 10/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.